VeriStrat results correlate with survival outcomes in advanced lung cancer
Results from the combined analysis of two European Phase II trials have been presented at the 3rd European Lung Cancer Conference in Geneva, Switzerland. Biodesix' VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy of Genentech's (Roche) Avastin (bevacizumab) and OSI Pharmaceuticals' (Astellas Pharma) Tarceva (erlotinib). Results showed that the VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
Pretreatment serum samples from 114 patients treated with bevacizumab+erlotinib were classified as either VeriStrat Good or VeriStrat Poor. The study showed there was a statistically significant difference in overall survival between the two groups. Patients classified as VeriStrat Good had a median overall survival of 13.4 months versus 6.2 months for patients classified as VeriStrat Poor (p=0.0027, HR=0.480, 95 per cent CI:0.294-0.784). Median progression free survival for patients classified as VeriStrat Good was 4 months and 3.2 months for patients classified as VeriStrat Poor, but this difference was not statistically significant (p=0.2632, HR=0.768, 95 per cent CI: 0.482-1.223).